$Evaluating the antifracture efficacy of bisphosphonates.$

Evaluating the antifracture efficacy of bisphosphonates.

Oral bisphosphonate dosing schedules have evolved from the original daily regimens to weekly (alendronate and risedronate) and monthly (risedronate and ibandronate) regimens. Intravenous (i.v.) bisphosphonates are administered less frequently-quarterly ibandronate injection and yearly zoledronic aci...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Pazianas, M, Epstein, S, Zaidi, M
Formato:	Journal article
Idioma:	English
Publicado em:	2009

Registos relacionados

Antifracture agents for prostate cancer patients on androgen deprivation therapy
Por: Bhupendra P Singh, et al.
Publicado em: (2010-01-01)

The sequential antifracturative treatment: a meta-analysis of randomized clinical trials
Por: Angelo Fassio, et al.
Publicado em: (2024-04-01)

Safety of bisphosphonates.
Por: Pazianas, M, et al.
Publicado em: (2011)

Bisphosphonates and bone quality.
Por: Pazianas, M, et al.
Publicado em: (2014)

Atrial fibrillation and bisphosphonate therapy.
Por: Pazianas, M, et al.
Publicado em: (2010)

Potential therapeutic effects of oral bisphosphonates on the intestine.
Por: Pazianas, M, et al.
Publicado em: (2011)

Safety issues with bisphosphonate therapy for osteoporosis.
Por: Suresh, E, et al.
Publicado em: (2014)

Are bisphosphonates associated with an increased risk of atypical femoral fractures as a class?
Por: Pazianas, M
Publicado em: (2013)

Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies
Por: Alexander J Rodríguez, et al.
Publicado em: (2022-06-01)

Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies
Por: Alexander J Rodríguez, et al.
Publicado em: (2021-07-01)

Bisphosphonates and colon cancer: reply.
Por: Pazianas, M, et al.
Publicado em: (2013)

Bisphosphonates and colon cancer: Reply
Por: Pazianas, M, et al.
Publicado em: (2013)

Eliminating the need for fasting with oral administration of bisphosphonates.
Por: Pazianas, M, et al.
Publicado em: (2013)

Eliminating the need for fasting with oral administration of bisphosphonates
Por: Pazianas M, et al.
Publicado em: (2013-10-01)

NE‐58025: A bisphosphonate with a low hydroxyapatite binding affinity
Por: Michael Pazianas
Publicado em: (2021-08-01)

Atrial fibrillation and the use of oral bisphosphonates.
Por: Pazianas, M, et al.
Publicado em: (2011)

Atrial fibrillation and the use of oral bisphosphonates
Por: Michael Pazianas, et al.
Publicado em: (2011-03-01)

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.
Por: Pazianas, M, et al.
Publicado em: (2010)

Findings of Danish study on risk of colon cancer in bisphosphonate users were misinterpreted.
Por: Abrahamsen, B, et al.
Publicado em: (2013)

NO ASSOCIATION BETWEEN THE USE OF ORAL BISPHOSPHONATES AND INCIDENCE OF ATRIAL FIBRILLATION
Por: Pazianas, M, et al.
Publicado em: (2010)

Comment on Tadrous et al.: comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.
Por: Pazianas, M, et al.
Publicado em: (2014)

Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker.
Por: Pazianas, M, et al.
Publicado em: (2008)

Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker: Reply to Yarom and Elad
Por: Pazianas, M, et al.
Publicado em: (2008)

A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Por: Pazianas, M, et al.
Publicado em: (2007)

Impact of bisphosphonates in age-related macular degeneration: Retrospective cohort and nested case-control study
Por: Garriga, C, et al.
Publicado em: (2018)

Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study.
Por: Pazianas, M, et al.
Publicado em: (2012)

Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database.
Por: Pazianas, M, et al.
Publicado em: (2013)

Oral bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study
Por: Garriga, C, et al.
Publicado em: (2018)

Impact of bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study
Por: Garriga, C, et al.
Publicado em: (2018)

Bisphosphonates and Age-Related Macular Degeneration: A Propensity-Matched Cohort and Nested Case-Control Analysis
Por: Garriga, C, et al.
Publicado em: (2017)

Bisphosphonates
Por: Bishop, N, et al.
Publicado em: (2013)

Bisphosphonates
Por: Fırat Öztürk
Publicado em: (2009-04-01)

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Por: Russell, R, et al.
Publicado em: (2007)

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Por: Russell, R, et al.
Publicado em: (2007)

Safety and efficacy of bisphosphonates in thalassemia patients with osteopenia/osteoporosis
Por: Sujata Sharma, et al.
Publicado em: (2023-04-01)

Efficacy of Bisphosphonates for the Treatment of Osteoporosis in Patients with Multiple Sclerosis
Por: İlke Coşkun Benlidayı, et al.
Publicado em: (2015-08-01)

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.
Por: Russell, R, et al.
Publicado em: (2008)

Bisphosphonates: An update
Por: Nalliappan Ganapathy, et al.
Publicado em: (2012-01-01)

Bisphosphonates 2006
Por: Russell, R
Publicado em: (2006)

Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Por: Pazianas, M, et al.
Publicado em: (2012)